Senate Bill No. 425–Committee on Commerce and Labor
(On Behalf of the Board of Pharmacy)
March 24, 2003
____________
Referred to Committee on Commerce and Labor
SUMMARY—Makes various changes relating to pharmacy. (BDR 54‑530)
FISCAL NOTE: Effect on Local Government: No.
Effect on the State: No.
~
EXPLANATION
– Matter in bolded italics is new; matter
between brackets [omitted material] is material to be omitted.
Green numbers along left margin indicate location on the printed bill (e.g., 5-15 indicates page 5, line 15).
THE PEOPLE OF THE STATE OF NEVADA, REPRESENTED IN
SENATE AND ASSEMBLY, DO ENACT AS FOLLOWS:
2-1 Section 1. Chapter 639 of NRS is hereby amended by adding
2-2 thereto the provisions set forth as sections 2 to 3.7, inclusive, of this
2-3 act.
2-4 Sec. 2. “Pharmaceutical technician” means a person who
2-5 performs technical services in a pharmacy under the direct
2-6 supervision of a pharmacist and is registered with the Board.
2-7 Sec. 3. “Pharmaceutical technician in training” means a
2-8 person who is:
2-9 1. Registered with the Board in order to obtain the training
2-10 and experience required to be a pharmaceutical technician; or
2-11 2. Enrolled in a program of training for pharmaceutical
2-12 technicians that is approved by the Board.
2-13 Sec. 3.5. 1. A wholesaler may sell a prescription drug only
2-14 to:
2-15 (a) A pharmacy or practitioner; or
2-16 (b) Another wholesaler if:
2-17 (1) The wholesaler who purchases the drug is licensed by
2-18 the Board or the board or other relevant authority of another
2-19 state; and
2-20 (2) The sale is a bona fide transaction.
2-21 2. A wholesaler may purchase a prescription drug only from:
2-22 (a) A manufacturer; or
2-23 (b) Another wholesaler if:
2-24 (1) The wholesaler who sells the drug is licensed by the
2-25 Board or the board or other relevant authority of another state;
2-26 and
2-27 (2) The sale is a bona fide transaction.
2-28 3. The Board shall not limit the quantity of prescription drugs
2-29 a wholesaler may purchase, sell, distribute or otherwise provide to
2-30 another wholesaler, distributor or manufacturer.
2-31 4. For the purposes of this section:
2-32 (a) A purchase shall be deemed a bona fide transaction if:
2-33 (1) The wholesaler purchased the drug:
2-34 (I) Directly from the manufacturer of the drug; or
2-35 (II) With a reasonable belief that the drug was
2-36 originally purchased directly from the manufacturer of the drug;
2-37 (2) The circumstances of the purchase reasonably indicate
2-38 that the drug was not purchased from a source prohibited by law;
2-39 (3) Unless the drug is purchased by the wholesaler from the
2-40 manufacturer, before the wholesaler sells the drug to another
2-41 wholesaler, the wholesaler who sells the drug conducts a
2-42 reasonable visual examination of the drug to ensure that the drug
2-43 is not:
2-44 (I) Counterfeit;
3-1 (II) Deemed to be adulterated or misbranded in
3-2 accordance with the provisions of chapter 585 of NRS;
3-3 (III) Mislabeled;
3-4 (IV) Damaged or compromised by improper handling,
3-5 storage or temperature control;
3-6 (V) From a foreign or unlawful source; or
3-7 (VI) Manufactured, packaged, labeled or shipped in
3-8 violation of any state or federal law relating to prescription drugs;
3-9 (4) The drug is shipped directly from the wholesaler who
3-10 sells the drug to the wholesaler who purchases the drug; and
3-11 (5) The documents of the shipping company concerning the
3-12 shipping of the drug are attached to the invoice for the drug and
3-13 are maintained in the records of the wholesaler.
3-14 (b) A sale shall be deemed a bona fide transaction if there is a
3-15 reasonable assurance by the wholesaler that purchases the drug
3-16 that the wholesaler will sell the drug directly and only to a
3-17 pharmacy or practitioner.
3-18 (c) The purchase or sale of a prescription drug includes,
3-19 without limitation, the distribution, transfer, trading, bartering or
3-20 any other provision of a prescription drug to another person by a
3-21 wholesaler. A transfer of a prescription drug from a wholesale
3-22 facility of a wholesaler to another wholesale facility of the
3-23 wholesaler shall not be deemed a purchase or sale of a
3-24 prescription drug pursuant to this section if the wholesaler is a
3-25 corporation whose securities are publicly traded and regulated by
3-26 the Securities Exchange Act of 1934.
3-27 Sec. 3.7. 1. A pharmacist shall not refuse to fill or refill a
3-28 prescription as written unless the pharmacist knows or has
3-29 reasonable cause to believe that the prescription is:
3-30 (a) Fraudulent;
3-31 (b) Issued contrary to law; or
3-32 (c) Contraindicated.
3-33 2. If a pharmacist refuses to dispense a prescription pursuant
3-34 to paragraph (c) of subsection 1, the pharmacist shall consult with
3-35 the prescribing practitioner as soon as practicable.
3-36 3. The provisions of this section do not:
3-37 (a) Require a pharmacist to stock a particular drug; or
3-38 (b) Prohibit a pharmacist from:
3-39 (1) Substituting a drug pursuant to NRS 639.2583; or
3-40 (2) Requiring payment for a drug in the normal course of
3-41 business.
3-42 Sec. 4. NRS 639.001 is hereby amended to read as follows:
3-43 639.001 As used in this chapter, unless the context otherwise
3-44 requires, the words and terms defined in NRS 639.0015 to 639.016,
4-1 inclusive, and sections 2 and 3 of this act have the meanings
4-2 ascribed to them in those sections.
4-3 Sec. 5. NRS 639.0124 is hereby amended to read as follows:
4-4 639.0124 “Practice of pharmacy” includes, but is not limited
4-5 to, the:
4-6 1. Performance or supervision of activities associated with
4-7 manufacturing, compounding, labeling, dispensing and distributing
4-8 of a drug[.] , including the receipt, handling and storage of
4-9 prescriptions and other confidential information relating to
4-10 patients.
4-11 2. Interpretation and evaluation of prescriptions or orders for
4-12 medicine.
4-13 3. Participation in drug evaluation and drug research.
4-14 4. Advising of the therapeutic value, reaction, drug interaction,
4-15 hazard and use of a drug.
4-16 5. Selection of the source, storage and distribution of a drug.
4-17 6. Maintenance of proper documentation of the source, storage
4-18 and distribution of a drug.
4-19 7. Interpretation of clinical data contained in a person’s record
4-20 of medication.
4-21 8. Development of written guidelines and protocols in
4-22 collaboration with a practitioner which are intended for a patient in a
4-23 licensed medical facility and authorize the implementation,
4-24 monitoring and modification of drug therapy. The written
4-25 guidelines and protocols may authorize a pharmacist to order and
4-26 use the findings of laboratory tests and examinations.
4-27 9. Implementation and modification of drug therapy in
4-28 accordance with the authorization of the prescribing practitioner for
4-29 a patient in a pharmacy in which drugs, controlled substances,
4-30 poisons, medicines or chemicals are sold at retail.
4-31 The term does not include the changing of a prescription by a
4-32 pharmacist or practitioner without the consent of the prescribing
4-33 practitioner, except as otherwise provided in NRS 639.2583.
4-34 Sec. 6. NRS 639.015 is hereby amended to read as follows:
4-35 639.015 “Registered pharmacist” means:
4-36 1. A person registered in this state as such on July 1, 1947;
4-37 2. A person registered in this state as such in compliance with
4-38 the provisions of paragraph (c) of section 3 of chapter 195, Statutes
4-39 of Nevada 1951; or
4-40 3. A person who has complied with the provisions of NRS
4-41 639.120 [and 639.133] and whose name has been entered in the
4-42 registry of pharmacists of this state by the Executive Secretary of
4-43 the Board and to whom a valid certificate as a registered pharmacist
4-44 or valid renewal thereof has been issued by the Board.
4-45 Sec. 7. (Deleted by amendment.)
5-1 Sec. 8. NRS 639.040 is hereby amended to read as follows:
5-2 639.040 1. The Board shall elect a President and a Treasurer
5-3 from among its members.
5-4 2. The Board shall employ [a] an Executive Secretary, who
5-5 must not be a member of the Board. The Executive Secretary shall
5-6 keep a complete record of all proceedings of the Board and of all
5-7 certificates issued, and shall perform such other duties as the Board
5-8 may require, for which services he is entitled to receive a salary to
5-9 be determined by the Board.
5-10 Sec. 9. NRS 639.070 is hereby amended to read as follows:
5-11 639.070 1. The Board may:
5-12 (a) Adopt such regulations, not inconsistent with the laws of this
5-13 state, as are necessary for the protection of the public, appertaining
5-14 to the practice of pharmacy and the lawful performance of its duties.
5-15 (b) Adopt regulations requiring that prices charged by retail
5-16 pharmacies for drugs and medicines which are obtained by
5-17 prescription be posted in the pharmacies and be given on the
5-18 telephone to persons requesting such information.
5-19 (c) Adopt regulations, not inconsistent with the laws of this
5-20 state, authorizing the Executive Secretary of the Board to issue
5-21 certificates, licenses and permits required by this chapter and
5-22 chapters 453 and 454 of NRS.
5-23 (d) Adopt regulations governing the dispensing of poisons,
5-24 drugs, chemicals and medicines.
5-25 (e) Regulate the practice of pharmacy.
5-26 (f) Regulate the sale and dispensing of poisons, drugs, chemicals
5-27 and medicines.
5-28 (g) Regulate the means of recordkeeping and storage, handling,
5-29 sanitation and security of drugs, poisons, medicines, chemicals and
5-30 devices, including, but not limited to, requirements relating to:
5-31 (1) Pharmacies, institutional pharmacies and pharmacies in
5-32 correctional institutions;
5-33 (2) Drugs stored in hospitals; and
5-34 (3) Drugs stored for the purpose of wholesale distribution.
5-35 (h) Examine and register, upon application, pharmacists and
5-36 other persons who dispense or distribute medications whom it
5-37 deems qualified.
5-38 (i) Charge and collect necessary and reasonable fees for its
5-39 services, other than those specifically set forth in this chapter.
5-40 (j) Maintain offices in as many localities in the State as it finds
5-41 necessary to carry out the provisions of this chapter.
5-42 (k) Employ an attorney, inspectors, investigators and other
5-43 professional consultants and clerical personnel necessary to the
5-44 discharge of its duties.
6-1 (l) Enforce the provisions of NRS 453.011 to 453.552, inclusive,
6-2 and enforce the provisions of this chapter and chapter 454 of NRS.
6-3 (m) Adopt regulations concerning the information required to be
6-4 submitted in connection with an application for any license,
6-5 certificate or permit required by this chapter or chapter 453 or 454
6-6 of NRS.
6-7 (n) Adopt regulations concerning the education, experience and
6-8 background of a person who is employed by the holder of a license
6-9 or permit issued pursuant to this chapter and who has access to
6-10 drugs and devices.
6-11 (o) Adopt regulations concerning the use of computerized
6-12 mechanical equipment for the filling of prescriptions.
6-13 (p) Participate in and expend money for programs that enhance
6-14 the practice of pharmacy.
6-15 2. This section does not authorize the Board to prohibit open-
6-16 market competition in the advertising and sale of prescription drugs
6-17 and pharmaceutical services.
6-18 Sec. 10. NRS 639.081 is hereby amended to read as follows:
6-19 639.081 1. Except as otherwise provided in subsection 3, all
6-20 money coming into the possession of the Board must be kept or
6-21 deposited by the Executive Secretary of the Board in banks, credit
6-22 unions or savings and loan associations in the State of Nevada, or
6-23 invested in United States treasury bills or notes, to be expended for
6-24 payment of compensation and expenses of members of the Board
6-25 and for other necessary or proper purposes in the administration of
6-26 this chapter.
6-27 2. The Board may delegate to a hearing officer or panel its
6-28 authority to take any disciplinary action pursuant to this chapter,
6-29 impose and collect fines therefor and deposit the money therefrom
6-30 in banks, credit unions or savings and loan associations in this state.
6-31 3. If a hearing officer or panel is not authorized to take
6-32 disciplinary action pursuant to subsection 2 and the Board deposits
6-33 the money collected from the imposition of fines with the State
6-34 Treasurer for credit to the State General Fund, it may present a
6-35 claim to the State Board of Examiners for recommendation to the
6-36 Interim Finance Committee if money is needed to pay attorney’s
6-37 fees or the costs of an investigation, or both.
6-38 Sec. 11. NRS 639.120 is hereby amended to read as follows:
6-39 639.120 1. An applicant to become a registered pharmacist in
6-40 this state must:
6-41 (a) Be of good moral character.
6-42 (b) Be a graduate of a college of pharmacy or department of
6-43 pharmacy of a university accredited by the American Council on
6-44 Pharmaceutical Education or Canadian Council for Accreditation
6-45 of Pharmacy Programs and approved by the Board or a graduate of
7-1 a foreign school who has passed an examination for foreign
7-2 graduates approved by the Board to demonstrate that his education
7-3 is equivalent.
7-4 (c) Pass an examination approved and given by the Board with a
7-5 grade of at least 75 on the examination as a whole and a grade of at
7-6 least 75 on the examination on law. An applicant for registration by
7-7 reciprocity must pass the examination on law with at least a grade
7-8 of 75.
7-9 (d) Complete not less than 1,500 hours of practical
7-10 pharmaceutical experience as an intern pharmacist under the direct
7-11 and immediate supervision of a registered pharmacist.
7-12 2. The practical pharmaceutical experience required pursuant
7-13 to paragraph (d) of subsection 1 must relate primarily to the selling
7-14 of drugs, poisons and devices, the compounding and dispensing of
7-15 prescriptions, preparing prescriptions , and keeping records and
7-16 preparing reports required by state and federal statutes.
7-17 3. The Board may accept evidence of compliance with the
7-18 requirements set forth in paragraph (d) of subsection 1 from boards
7-19 of pharmacy of other states in which the experience requirement is
7-20 equivalent to the requirements in this state.
7-21 Sec. 12. NRS 639.127 is hereby amended to read as follows:
7-22 639.127 1. An applicant for registration as a pharmacist in
7-23 this state must submit an application to the Executive Secretary of
7-24 the Board on a form furnished by the Board and must pay the fee
7-25 fixed by the Board. The fee must be paid at the time the application
7-26 is submitted and is compensation to the Board for the investigation
7-27 and the examination of the applicant. Under no circumstances may
7-28 the fee be refunded.
7-29 2. Proof of the qualifications of any applicant must be made to
7-30 the satisfaction of the Board and must be substantiated by affidavits,
7-31 records or such other evidence as the Board may require.
7-32 3. An application is only valid for 1 year after the date it is
7-33 received by the Board unless the Board extends its period of
7-34 validity.
7-35 4. A certificate of registration as a pharmacist must be issued to
7-36 each person who the Board determines is qualified pursuant to the
7-37 provisions of NRS 639.120[, 639.133] and 639.134. The certificate
7-38 entitles the person to whom it is issued to practice pharmacy in this
7-39 state.
7-40 Sec. 13. NRS 639.128 is hereby amended to read as follows:
7-41 639.128 The application of a natural person who applies for the
7-42 issuance of a certificate of registration as a pharmacist, [an]
7-43 intern pharmacist [or supportive personnel] , pharmaceutical
7-44 technician or pharmaceutical technician in training or a license
8-1 issued pursuant to NRS 639.233 must include the social security
8-2 number of the applicant.
8-3 Sec. 14. NRS 639.129 is hereby amended to read as follows:
8-4 639.129 1. A natural person who applies for the issuance or
8-5 renewal of a certificate of registration as a pharmacist, [an]
8-6 intern pharmacist [or supportive personnel] , pharmaceutical
8-7 technician or pharmaceutical technician in training or a license
8-8 issued pursuant to NRS 639.233 shall submit to the Board the
8-9 statement prescribed by the Welfare Division of the Department of
8-10 Human Resources pursuant to NRS 425.520. The statement must be
8-11 completed and signed by the applicant.
8-12 2. The Board shall include the statement required pursuant to
8-13 subsection 1 in:
8-14 (a) The application or any other forms that must be submitted
8-15 for the issuance or renewal of the certificate or license; or
8-16 (b) A separate form prescribed by the Board.
8-17 3. A certificate of registration as a pharmacist, [an]
8-18 intern pharmacist [or supportive personnel] , pharmaceutical
8-19 technician or pharmaceutical technician in training or a license
8-20 issued issued pursuant to NRS 639.233 may not be issued or
8-21 renewed by the Board if the applicant is a natural person who:
8-22 (a) Fails to submit the statement required pursuant to
8-23 subsection 1; or
8-24 (b) Indicates on the statement submitted pursuant to subsection
8-25 1 that he is subject to a court order for the support of a child and is
8-26 not in compliance with the order or a plan approved by the district
8-27 attorney or other public agency enforcing the order for the
8-28 repayment of the amount owed pursuant to the order.
8-29 4. If an applicant indicates on the statement submitted pursuant
8-30 to subsection 1 that he is subject to a court order for the support of a
8-31 child and is not in compliance with the order or a plan approved by
8-32 the district attorney or other public agency enforcing the order for
8-33 the repayment of the amount owed pursuant to the order, the Board
8-34 shall advise the applicant to contact the district attorney or other
8-35 public agency enforcing the order to determine the actions that the
8-36 applicant may take to satisfy the arrearage.
8-37 Sec. 15. NRS 639.137 is hereby amended to read as follows:
8-38 639.137 1. Any person who is not a registered pharmacist,
8-39 but who is employed in this state for the purpose of fulfilling the
8-40 requirements of paragraph (d) of subsection 1 of NRS 639.120 to
8-41 become eligible for registration as a pharmacist, shall register with
8-42 the Board as an intern pharmacist. An applicant, to be eligible for
8-43 registration as an intern pharmacist, must be enrolled in a college of
8-44 pharmacy or a department of pharmacy of a university approved by
8-45 the Board or be a graduate of a foreign school and pass an
9-1 examination for foreign graduates approved by the Board. The
9-2 application must be made on a form furnished by the Board.
9-3 2. The Executive Secretary of the Board, upon approval of the
9-4 application, shall issue a certificate of registration authorizing
9-5 the applicant to undergo practical pharmaceutical training under the
9-6 direct and immediate supervision of a registered pharmacist. The
9-7 period of validity of the certificate of registration, including any
9-8 renewal, must not exceed 4 years after the date of issue. The
9-9 certificate of registration authorizes the holder, if acting under the
9-10 direct and immediate supervision of a registered pharmacist, to
9-11 perform:
9-12 (a) The duties of a registered pharmacist as authorized by
9-13 regulation of the Board; and
9-14 (b) Other activities as authorized by regulation of the Board.
9-15 3. The certificate of registration must be posted as required by
9-16 NRS 639.150.
9-17 4. Any certificate of registration issued pursuant to the
9-18 provisions of this section may be suspended, terminated or revoked
9-19 by the Board for:
9-20 (a) Any reason set forth in this chapter as grounds for the
9-21 suspension or revocation of any certificate, license or permit; or
9-22 (b) The failure of the registered pharmacist whose name appears
9-23 on the certificate of registration to provide adequate training and
9-24 supervision for the intern pharmacist in compliance with regulations
9-25 adopted by the Board.
9-26 Sec. 16. NRS 639.1371 is hereby amended to read as follows:
9-27 639.1371 1. The ratio of [supportive personnel]
9-28 pharmaceutical technicians to pharmacists must not allow more
9-29 than one [supportive personnel] pharmaceutical technician to each
9-30 pharmacist unless the Board by regulation expands the ratio.
9-31 2. The Board shall adopt regulations concerning[supportive
9-32 personnel,] pharmaceutical technicians, including requirements
9-33 for:
9-34 (a) The qualifications, registration and supervision of
9-35 [supportive personnel;] pharmaceutical technicians, and
9-36 (b) [Services] The services which may be performed by
9-37 [supportive personnel,] pharmaceutical technicians,
9-38 to ensure the protection and safety of the public in the provision of
9-39 pharmaceutical care.
9-40 3. The regulations adopted by the Board pursuant to this
9-41 section which prescribe:
9-42 (a) The qualifications for [supportive personnel]
9-43 pharmaceutical technicians must include:
10-1 (1) [At least 1 year of education at a postsecondary school
10-2 which is directly related to the duties performed by supportive
10-3 personnel;
10-4 (2)] The successful completion of a program for [supportive
10-5 personnel] pharmaceutical technicians which is approved by the
10-6 Board;
10-7 [(3)] (2) The completion of at least 1,500 hours of experience
10-8 in carrying out the duties of [supportive personnel; or
10-9 (4)] a pharmaceutical technician; or
10-10 (3) Any other experience or education deemed equivalent by
10-11 the Board.
10-12 (b) An expanded ratio of [supportive personnel] pharmaceutical
10-13 technicians to pharmacists must [not allow more than two
10-14 supportive personnel for each pharmacist in] be appropriate and
10-15 necessary for a particular category of pharmacy at any time.
10-16 (c) The services which may be performed by [supportive
10-17 personnel] pharmaceutical technicians must include, without
10-18 limitation, the:
10-19 (1) Removal of drugs from stock;
10-20 (2) Counting, pouring or mixing of drugs;
10-21 (3) Placing of drugs in containers;
10-22 (4) Affixing of labels to containers; and
10-23 (5) Packaging and repackaging of drugs.
10-24 4. For the purposes of this chapter, and chapters 453 and 454 of
10-25 NRS, [supportive personnel] pharmaceutical technicians may
10-26 perform acts required to be performed by pharmacists , but only to
10-27 the extent provided in regulations.
10-28 Sec. 17. NRS 639.138 is hereby amended to read as follows:
10-29 639.138 If the Board, after an investigation, denies any
10-30 application for a certificate, license or permit, the Executive
10-31 Secretary of the Board shall notify the applicant, within 10 days
10-32 after the denial is approved by the Board and entered in the official
10-33 minutes, by registered or certified mail, of the denial of the
10-34 application and the reasons therefor. The notice must inform the
10-35 applicant of his right to petition the Board for reconsideration and
10-36 his right to submit evidence to controvert the alleged violations on
10-37 which the denial was based.
10-38 Sec. 18. NRS 639.139 is hereby amended to read as follows:
10-39 639.139 1. At any time within 30 days after receipt of the
10-40 notice of denial of his application, an applicant may petition the
10-41 Board for reconsideration of the application. The petition must set
10-42 forth a denial, in whole or in part, of the violations alleged and a
10-43 statement that the applicant is prepared to submit evidence in
10-44 support of his denial of the allegations.
11-1 2. Within 30 days after the petition is received by the Board,
11-2 the Executive Secretary of the Board shall notify the petitioner, by
11-3 registered or certified mail, of the Board’s decision [either] to grant
11-4 or deny the petition for reconsideration. If the petition is granted, the
11-5 notice [shall] must include the time and place set for reconsideration
11-6 of the application by the Board.
11-7 Sec. 19. NRS 639.160 is hereby amended to read as follows:
11-8 639.160 Every registered pharmacist shall, within 10 days after
11-9 changing his place of practice as designated on the books of the
11-10 Executive Secretary of the Board, notify the Executive Secretary [of
11-11 the Board of such] of the change and of his new place of practice.
11-12 Upon receipt of [such] the notification , the Executive Secretary
11-13 shall make the necessary change in his register.
11-14 Sec. 20. NRS 639.170 is hereby amended to read as follows:
11-15 639.170 1. The Board shall charge and collect not more than
11-16 the following fees for the following services:
11-17 Actual cost
11-18 For the examination of an applicant for registration of the
11-19 as a pharmacist........................ examination
11-20 For the investigation or registration of an
11-21 applicant as a registered pharmacist$200
11-22 For the investigation, examination or registration
11-23 of an applicant as a registered pharmacist by
11-24 reciprocity........................................... 300
11-25 For the investigation or issuance of an original
11-26 license to conduct a retail pharmacy. 600
11-27 For the biennial renewal of a license to conduct a
11-28 retail pharmacy................................... 500
11-29 For the investigation or issuance of an original
11-30 license to conduct an institutional pharmacy 600
11-31 For the biennial renewal of a license to conduct an
11-32 institutional pharmacy........................ 500
11-33 For the issuance of an original or duplicate
11-34 certificate of registration as a registered
11-35 pharmacist............................................ 50
11-36 For the biennial renewal of registration as a
11-37 registered pharmacist......................... 200
11-38 For the reinstatement of a lapsed registration (in
11-39 addition to the fees for renewal for the period of
11-40 lapse)................................................... 100
11-41 [For the initial registration of supportive personnel........................... 50
11-42 For the biennial renewal of registration of
11-43 supportive personnel.......................... 50]
12-1 For the initial registration of a pharmaceutical
12-2 technician or pharmaceutical technician in
12-3 training............................................... $50
12-4 For the biennial renewal of registration of a
12-5 pharmaceutical technician or pharmaceutical
12-6 technician in training........................ 50
12-7 For the investigation or registration of an intern
12-8 pharmacist............................................. 50
12-9 For the biennial renewal of registration as an
12-10 intern pharmacist................................. 40
12-11 For investigation or issuance of an original license
12-12 to a manufacturer or wholesaler........ 500
12-13 For the biennial renewal of a license for a
12-14 manufacturer or wholesaler.... [400] 500
12-15 For the reissuance of a license issued to a
12-16 pharmacy, when no change of ownership is
12-17 involved, but the license must be reissued because
12-18 of a change in the information required thereon100
12-19 [For the biennial renewal of registration issued to
12-20 a registered pharmacist placed on inactive status 100]
12-21 For authorization of a practitioner to dispense
12-22 controlled substances or dangerous drugs, or both300
12-23 For the biennial renewal of authorization of a
12-24 practitioner to dispense controlled substances or
12-25 dangerous drugs, or both................... 300
12-26 2. If a person requests a special service from the Board or
12-27 requests the Board to convene a special meeting, he must pay the
12-28 actual costs to the Board as a condition precedent to the rendition of
12-29 the special service or the convening of the special meeting.
12-30 3. All fees are payable in advance and are not refundable.
12-31 4. The Board may, by regulation, set the penalty for failure to
12-32 pay the fee for renewal for any license, permit, authorization or
12-33 certificate within the statutory period, at an amount not to exceed
12-34 100 percent of the fee for renewal for each year of delinquency in
12-35 addition to the fees for renewal for each year of delinquency.
12-36 Sec. 21. NRS 639.180 is hereby amended to read as follows:
12-37 639.180 1. Except as otherwise provided in this subsection, a
12-38 certificate, license or permit issued by the Board pursuant to this
12-39 chapter expires on October 31 of each even‑numbered year. A
12-40 certificate of registration as a pharmacist expires on October 31 of
12-41 each odd‑numbered year.
13-1 2. Except as otherwise provided by NRS 639.137, 639.230 and
13-2 639.2328, each person to whom a certificate, license or permit has
13-3 been issued may, if the certificate, license or permit has not been
13-4 revoked, renew the certificate, license or permit biennially by:
13-5 (a) Filing an application for renewal;
13-6 (b) Paying the fee for renewal;
13-7 (c) Complying with the requirement of continuing professional
13-8 education, if applicable; and
13-9 (d) If the applicant is a natural person who is applying for the
13-10 renewal of a certificate of registration as a pharmacist, [an]
13-11 intern pharmacist [or supportive personnel] , pharmaceutical
13-12 technician or pharmaceutical technician in training or a license
13-13 issued pursuant to NRS 639.233, submitting the statement required
13-14 pursuant to NRS 639.129.
13-15 3. The application for renewal, together with the fee for
13-16 renewal and, if applicable, the statement, must be delivered to the
13-17 Executive Secretary of the Board on or before the expiration date of
13-18 the certificate, license or permit, or the current renewal receipt
13-19 thereof.
13-20 4. If a certificate, license or permit is renewed, it must be
13-21 delivered to the applicant within a reasonable time after receipt of
13-22 the application for renewal and the fee for renewal.
13-23 5. The Board may refuse to renew a certificate, license or
13-24 permit if the applicant has committed any act proscribed by
13-25 NRS 639.210.
13-26 6. If the application for renewal and the fee for renewal and, if
13-27 applicable, the statement[,] are not postmarked on or before the
13-28 expiration date of the certificate, license or permit, or the current
13-29 renewal receipt thereof, the registration is automatically forfeited.
13-30 Sec. 22. NRS 639.2174 is hereby amended to read as follows:
13-31 639.2174 The Board shall not[:
13-32 1. Issue a certificate as a registered pharmacist to any person
13-33 pursuant to NRS 639.133; or
13-34 2. Renew] renew the certificate of any registered pharmacist[,]
13-35 until the applicant has submitted proof to the Board of the receipt of
13-36 the required number of continuing education units, obtained through
13-37 the satisfactory completion of an accredited program of continuing
13-38 professional education during the period for which the certificate
13-39 was issued.
13-40 Sec. 23. NRS 639.230 is hereby amended to read as follows:
13-41 639.230 1. A [pharmacy or a] person operating [as a
13-42 pharmacy] a business in this state shall not use the letters “Rx” or
13-43 “RX” or the word “drug” or “drugs,” “prescription” or “pharmacy,”
13-44 or similar words or words of similar import, without first having
13-45 secured a license from the Board.
14-1 2. Each license must be issued to a specific person and for a
14-2 specific location and is not transferable. The original license must be
14-3 displayed on the licensed premises as provided in NRS 639.150.
14-4 The original license and the fee required for reissuance of a license
14-5 must be submitted to the Board before the reissuance of the license.
14-6 3. If the owner of a pharmacy is a partnership or corporation,
14-7 any change of partners or corporate officers must be reported to the
14-8 Board at such a time as is required by a regulation of the Board.
14-9 4. In addition to the requirements for renewal set forth in NRS
14-10 639.180, every person holding a license to operate a pharmacy must
14-11 satisfy the Board that the pharmacy is conducted according to law.
14-12 5. Any violation of any of the provisions of this chapter by a
14-13 managing pharmacist or by personnel of the pharmacy under the
14-14 supervision of the managing pharmacist is cause for the suspension
14-15 or revocation of the license of the pharmacy by the Board.
14-16 Sec. 24. NRS 639.231 is hereby amended to read as follows:
14-17 639.231 1. An application to conduct a pharmacy must be
14-18 made on a form furnished by the Board and must state the name,
14-19 address, usual occupation and professional qualifications, if any, of
14-20 the applicant. If the applicant is other than a natural person, the
14-21 application must state such information as to each person
14-22 beneficially interested therein.
14-23 2. As used in subsection 1, and subject to the provisions of
14-24 subsection 3, the term “person beneficially interested” means:
14-25 (a) If the applicant is a partnership or other unincorporated
14-26 association, each partner or member.
14-27 (b) If the applicant is a corporation, each of its officers, directors
14-28 and stockholders, provided that no natural person shall be deemed to
14-29 be beneficially interested in a nonprofit corporation.
14-30 3. If the applicant is a partnership, unincorporated association
14-31 or corporation and the number of partners, members or stockholders,
14-32 as the case may be, exceeds four, the application must so state, and
14-33 must list each of the four partners, members or stockholders who
14-34 own the four largest interests in the applicant entity and state their
14-35 percentages of interest. Upon request of the Executive Secretary of
14-36 the Board, the applicant shall furnish the Board with information as
14-37 to partners, members or stockholders not named in the application or
14-38 shall refer the Board to an appropriate source of such information.
14-39 4. The completed application form must be returned to the
14-40 Board with the fee prescribed by the Board, which may not be
14-41 refunded. Any application which is not complete as required by the
14-42 provisions of this section may not be presented to the Board for
14-43 consideration.
14-44 5. Upon compliance with all the provisions of this section and
14-45 upon approval of the application by the Board, the Executive
15-1 Secretary shall issue a license to the applicant to conduct a
15-2 pharmacy. Any other provision of law notwithstanding, such a
15-3 license authorizes the holder to conduct a pharmacy and to sell and
15-4 dispense drugs and poisons and devices and appliances that are
15-5 restricted by federal law to sale by or on the order of a physician.
15-6 Sec. 24.5. NRS 639.233 is hereby amended to read as follows:
15-7 639.233 1. Any person, including a wholesaler or
15-8 manufacturer, who engages in the business of wholesale distribution
15-9 or furnishing controlled substances, poisons, drugs, devices or
15-10 appliances that are restricted by federal law to sale by or on the
15-11 order of a physician to any person located within this state shall
15-12 obtain a license pursuant to the provisions of this chapter.
15-13 2. [The provisions of subsection 1 do not apply to a wholesaler
15-14 or manufacturer whose principal place of business is located in
15-15 another state and who ships controlled substances, drugs, poisons or
15-16 restricted devices or appliances to a wholesaler or manufacturer
15-17 located within this state and licensed by the Board.
15-18 3.] For the purpose of this section, a person is “engaged in the
15-19 business of furnishing” if he:
15-20 (a) Solicits or accepts orders for drugs or devices whose sale in
15-21 this state is restricted by this chapter or chapter 453 or 454 of NRS;
15-22 or
15-23 (b) Receives, stores or ships such drugs or devices.
15-24 Sec. 25. NRS 639.234 is hereby amended to read as follows:
15-25 639.234 1. The acceptance of a license issued pursuant to
15-26 NRS 639.233 constitutes a consent by the licensee to the inspection
15-27 , copying and removal for copying of his records maintained inside
15-28 and outside this state by any authorized representative of the Board.
15-29 2. If such a licensee is not a resident of this state and does not
15-30 maintain records within this state of his shipments of controlled
15-31 substances, poisons or drugs or devices or appliances that are
15-32 restricted by federal law to sale by or on the order of a physician to
15-33 persons in this state , he shall, on receipt of a written demand from
15-34 the Executive Secretary of the Board, furnish a true copy of the
15-35 records to the Board.
15-36 3. The Board may authorize as its representative any member
15-37 or representative of the Board of pharmacy or similar agency of the
15-38 state in which the records are located.
15-39 4. [Failure] The failure to furnish a true copy of the required
15-40 records or the refusal to permit their inspection is a ground for [the
15-41 revocation or] suspension of and disciplinary action relating to any
15-42 license issued pursuant to NRS 639.233.
15-43 Sec. 26. NRS 639.235 is hereby amended to read as follows:
15-44 639.235 1. No person other than a practitioner holding a
15-45 license to practice his profession in this state may prescribe or write
16-1 a prescription, except that a prescription written by a person who is
16-2 not licensed to practice in this state , but is authorized by the laws of
16-3 another state to prescribe , shall be deemed to be a legal prescription
16-4 unless the person prescribed or wrote the prescription in violation of
16-5 the provisions of NRS 453.3611 to 453.3648, inclusive.
16-6 2. If a prescription that is prescribed by a person who is not
16-7 licensed to practice in this state, but is authorized by the laws of
16-8 another state to prescribe, calls for a controlled substance listed in:
16-9 (a) Schedule II, the registered pharmacist who is to fill the
16-10 prescription shall establish and document that the prescription is
16-11 authentic and that a bona fide relationship between the patient and
16-12 the person prescribing the controlled substance did exist when the
16-13 prescription was written.
16-14 (b) Schedule III or IV, the registered pharmacist who is to fill
16-15 the prescription shall establish[, in his professional judgment,] that
16-16 the prescription is authentic and that a bona fide relationship
16-17 between the patient and the person prescribing the controlled
16-18 substance did exist when the prescription was written. This
16-19 paragraph does not require the registered pharmacist to inquire into
16-20 such a relationship upon the receipt of [each such prescription.] a
16-21 similar prescription subsequently issued for that patient.
16-22 3. A pharmacist who fills a prescription described in
16-23 subsection 2 shall record on the prescription or in the prescription
16-24 record in the pharmacy’s computer:
16-25 (a) The name of the person with whom he spoke concerning
16-26 the prescription;
16-27 (b) The date and time of the conversation; and
16-28 (c) The date and time the patient was physically examined by
16-29 the person prescribing the controlled substance for which the
16-30 prescription was issued.
16-31 4. For the purposes of subsection 2, a bona fide relationship
16-32 between the patient and the person prescribing the controlled
16-33 substance shall be deemed to exist if the patient was physically
16-34 examined by the person prescribing the controlled substances
16-35 within the 6 months immediately preceding the date the
16-36 prescription was issued.
16-37 Sec. 27. NRS 639.238 is hereby amended to read as follows:
16-38 639.238 1. Prescriptions filled and on file in a pharmacy are
16-39 not a public record. A pharmacist shall not divulge the contents of
16-40 any prescription or provide a copy of any prescription, except to:
16-41 (a) The patient for whom the original prescription was issued;
16-42 (b) The practitioner who originally issued the prescription;
16-43 (c) A practitioner who is then treating the patient;
17-1 (d) A member, inspector or investigator of the Board or an
17-2 inspector of the Food and Drug Administration or an agent of the
17-3 Investigation Division of the Department of Public Safety;
17-4 (e) An agency of State Government charged with the
17-5 responsibility of providing medical care for the patient;
17-6 (f) An insurance carrier, on receipt of written authorization
17-7 signed by the patient or his legal guardian, authorizing the release of
17-8 such information;
17-9 (g) Any person authorized by an order of a district court;
17-10 (h) Any member, inspector or investigator of a professional
17-11 licensing board which licenses a practitioner who orders
17-12 prescriptions filled at the pharmacy; [or]
17-13 (i) Other registered pharmacists for the limited purpose of and to
17-14 the extent necessary for the exchange of information relating to
17-15 persons who are suspected of:
17-16 (1) Misusing prescriptions to obtain excessive amounts of
17-17 drugs[.] ; or
17-18 (2) Failing to use a drug in conformity with the directions for
17-19 its use or taking a drug in combination with other drugs in a manner
17-20 that could result in injury to that person[.] ; or
17-21 (j) A peace officer employed by a local government for the
17-22 limited purpose of and to the extent necessary:
17-23 (1) For the investigation of an alleged crime reported by an
17-24 employee of the pharmacy where the crime was committed; or
17-25 (2) To carry out a search warrant or subpoena issued
17-26 pursuant to a court order.
17-27 2. Any copy of a prescription for a controlled substance or a
17-28 dangerous drug as defined in chapter 454 of NRS, issued to a person
17-29 authorized by this section to receive such a copy, must contain all of
17-30 the information appearing on the original prescription and be clearly
17-31 marked on its face[,] “Copy, Not Refillable—For Reference
17-32 Purposes Only.” The copy must bear the name or initials of the
17-33 registered pharmacist who prepared the copy.
17-34 3. If a copy of a prescription for any controlled substance or a
17-35 dangerous drug as defined in chapter 454 of NRS is furnished to the
17-36 customer, the original prescription must be voided and notations
17-37 made thereon showing the date and the name of the person to whom
17-38 the copy was furnished.
17-39 4. If, at the express request of a customer, a copy of a
17-40 prescription for any controlled substance or dangerous drug is
17-41 furnished to another pharmacist, the original prescription must be
17-42 voided and notations made thereon showing the date and the name
17-43 of the pharmacist to whom the copy was furnished. The pharmacist
17-44 receiving the copy shall call the prescribing practitioner for a new
17-45 prescription.
18-1 5. As used in this section, “peace officer” does not include:
18-2 (a) A member of the Police Department of the University and
18-3 Community College System of Nevada.
18-4 (b) A school police officer who is appointed or employed
18-5 pursuant to NRS 391.100.
18-6 Sec. 28. NRS 639.239 is hereby amended to read as follows:
18-7 639.239 Members, inspectors and investigators of the Board,
18-8 inspectors of the Food and Drug Administration , [and] agents of the
18-9 Investigation Division of the Department of Public Safety and peace
18-10 officers described in paragraph (j) of subsection 1 of NRS 639.238
18-11 may remove any record required to be retained by state or federal
18-12 law or regulation, including any prescription contained in the files of
18-13 a practitioner, if the record in question will be used as evidence in a
18-14 criminal action, civil action or an administrative proceeding, or
18-15 contemplated action or proceeding. The person who removes a
18-16 record pursuant to this section shall:
18-17 1. Affix the name and address of the practitioner to the back of
18-18 the record;
18-19 2. Affix his initials, cause an agent of the practitioner to affix
18-20 his initials and note the date of the removal of the record on the back
18-21 of the record;
18-22 3. Affix the name of the agency for which he is removing the
18-23 record to the back of the record;
18-24 4. Provide the practitioner with a receipt for the record; and
18-25 5. Return a photostatic copy of both sides of the record to the
18-26 practitioner within 15 working days after the record is removed.
18-27 Sec. 29. NRS 639.241 is hereby amended to read as follows:
18-28 639.241 1. A hearing to determine whether the rights and
18-29 privileges granted by any certificate, certification, license or permit
18-30 issued by the Board should be revoked, suspended, limited or
18-31 conditioned must be initiated by the filing of an accusation by the
18-32 Board. The action must be entitled: The Nevada State Board of
18-33 Pharmacy v. (insert the name of the party whose certificate, license
18-34 or permit is involved), who must be designated “Respondent.”
18-35 2. The accusation is a written statement of the charges alleged
18-36 and must set forth in ordinary and concise language the acts or
18-37 omissions with which the respondent is charged to the end that the
18-38 respondent will be able to prepare his defense. [It] The accusation
18-39 must specify the statutes and regulations which the respondent is
18-40 alleged to have violated, but must not consist merely of charges
18-41 phrased in language of the statute or regulation. The accusation must
18-42 be signed by the Executive Secretary of the Board acting in his
18-43 official capacity.
19-1 Sec. 30. NRS 639.242 is hereby amended to read as follows:
19-2 639.242 1. After filing the accusation, the Executive
19-3 Secretary of the Board shall cause a copy thereof, together with one
19-4 copy of the Statement to Respondent and three copies of the form of
19-5 the Notice of Defense, to be served on the respondent.
19-6 2. Service may be [either] by personal service or by first-class
19-7 registered or certified mail addressed to the respondent at his last
19-8 address of record, or by mail to his attorney of record. Proof of
19-9 service [shall] must be retained and made a part of the case record.
19-10 Sec. 31. NRS 639.244 is hereby amended to read as follows:
19-11 639.244 1. The form for the Notice of Defense [shall] must
19-12 be prepared and furnished by the Board and [shall] permit the
19-13 respondent, by completing and signing the notice , to:
19-14 (a) [Request a hearing;
19-15 (b)] Object to the accusation as being incomplete and failing to
19-16 set forth clearly the charges; and
19-17 [(c)] (b) Deny or admit, in part or in whole, the violations
19-18 alleged.
19-19 2. The Notice of Defense [shall] must be signed by the
19-20 respondent or [by] his attorney under penalty of perjury. Failure to
19-21 file a Notice of Defense [and request a hearing shall constitute]
19-22 constitutes a waiver of the respondent’s right to a hearing, but the
19-23 Board may[, in its discretion,] grant a hearing.
19-24 Sec. 32. NRS 639.245 is hereby amended to read as follows:
19-25 639.245 Whenever a hearing has been granted by the Board,
19-26 the Executive Secretary of the Board shall serve notice on the
19-27 respondent of the time and place set for the hearing on the
19-28 accusation. If the Board receives a report pursuant to subsection 5 of
19-29 NRS 228.420, a hearing must be held within 30 days after receiving
19-30 the report. Service may be effected in the same manner as provided
19-31 in NRS 639.242.
19-32 Sec. 33. NRS 639.246 is hereby amended to read as follows:
19-33 639.246 1. The Executive Secretary of the Board shall issue
19-34 subpoenas for the production of witnesses, documents or papers, in
19-35 accordance with statutory provisions, at the request of any party to a
19-36 hearing or for purposes of an investigation or other matter under
19-37 inquiry by the Board.
19-38 2. Witnesses appearing pursuant to a subpoena must receive
19-39 expenses and witness fees in the amounts and under the same
19-40 circumstances as prescribed by law for witnesses in civil actions.
19-41 The expenses and fees must be paid in full by the party at whose
19-42 request the witness is subpoenaed.
19-43 3. Subpoenas must be served in the same manner as prescribed
19-44 by law for the service of subpoenas in civil actions. If any person
19-45 fails to comply with a subpoena within 10 days after its issuance, the
20-1 President of the Board, or the Executive Secretary of the Board at
20-2 the direction of the President, may petition the district court for an
20-3 order of the court compelling compliance with the subpoena.
20-4 4. Upon such a petition, the court shall enter an order directing
20-5 the person subpoenaed to appear before the court at a time and place
20-6 to be fixed by the court in its order, the time to be not more than 10
20-7 days after the date of the order, and then and there to show cause
20-8 why he has not complied with the subpoena. A certified copy of the
20-9 order must be served upon the person.
20-10 5. If it appears to the court that the subpoena was regularly
20-11 issued by the Board, the court shall enter an order compelling
20-12 compliance with the subpoena. Failure to obey the order constitutes
20-13 contempt of court.
20-14 Sec. 34. NRS 639.247 is hereby amended to read as follows:
20-15 639.247 1. Any hearing held for the purpose of suspending or
20-16 revoking any certificate, certification, license or permit must be
20-17 conducted publicly by the Board. The hearing must be presided over
20-18 by a member of the Board or his designee and three members
20-19 constitute a quorum. Any decision by the Board requires the
20-20 concurrence of at least three members. The proceedings of the
20-21 hearing must be reported or recorded by an electronic recording
20-22 device, an official court reporter or another qualified person.
20-23 2. The member of the Board or his designee presiding at the
20-24 hearing or the Executive Secretary of the Board may administer
20-25 oaths or affirmations. Continuances and adjournments may be
20-26 ordered, or may be granted, by the member or his designee
20-27 presiding, for cause shown and by orally notifying those persons
20-28 present of the time and place at which the hearing will be continued.
20-29 Sec. 35. NRS 639.252 is hereby amended to read as follows:
20-30 639.252 1. If the respondent wishes to contest or appeal the
20-31 decision of the Board, the order or any part thereof, he may, [prior
20-32 to] not later than 10 days after the time the order becomes
20-33 effective, apply in writing to the Board for a rehearing. [Such
20-34 application shall] The application must set forth with particularity
20-35 the part or parts of the decision or order to which the respondent
20-36 objects and the basis of the objection.
20-37 2. The Executive Secretary of the Board shall, within 10 days
20-38 after receipt of a written application for rehearing, notify the
20-39 respondent and his attorney of record in writing, by registered or
20-40 certified mail, of [its] his action, either granting or denying [such]
20-41 the application. If the application is granted, the notice [shall] must
20-42 contain the date, time and place of the rehearing . [, which date shall
20-43 not be less than 30 days after the date of the notice.] The rehearing
20-44 must be held at the next regularly scheduled meeting of the Board.
20-45 Granting of the application by the [Board shall serve] Executive
21-1 Secretary does not serve as an automatic stay of execution of the
21-2 order pending conclusion of the rehearing.
21-3 Sec. 36. NRS 639.2555 is hereby amended to read as follows:
21-4 639.2555 1. If the Board receives a copy of a court order
21-5 issued pursuant to NRS 425.540 that provides for the suspension of
21-6 all professional, occupational and recreational licenses, certificates
21-7 and permits issued to a person who is the holder of a certificate of
21-8 registration as a pharmacist, [an] intern pharmacist [or supportive
21-9 personnel] , pharmaceutical technician or pharmaceutical
21-10 technician in training or a license issued pursuant to NRS 639.223,
21-11 the Board shall deem the certificate of registration or license issued
21-12 to that person to be suspended at the end of the 30th day after the
21-13 date on which the court order was issued unless the Board receives a
21-14 letter issued to the holder of the certificate of registration or license
21-15 by the district attorney or other public agency pursuant to NRS
21-16 425.550 stating that the holder of the certificate of registration or
21-17 license has complied with the subpoena or warrant or has satisfied
21-18 the arrearage pursuant to NRS 425.560.
21-19 2. The Board shall reinstate a certificate of registration as a
21-20 pharmacist, [an] intern pharmacist [or supportive personnel] ,
21-21 pharmaceutical technician or pharmaceutical technician in
21-22 training or a license issued pursuant to NRS 639.233 that has been
21-23 suspended by a district court pursuant to NRS 425.540 if the Board
21-24 receives a letter issued by the district attorney or other public agency
21-25 pursuant to NRS 425.550 to the person whose certificate of
21-26 registration or license was suspended stating that the person whose
21-27 certificate of registration or license was suspended has complied
21-28 with the subpoena or warrant or has satisfied the arrearage pursuant
21-29 to NRS 425.560.
21-30 Sec. 37. NRS 639.256 is hereby amended to read as follows:
21-31 639.256 A certificate, license or permit which has been
21-32 suspended for a specified period of time [shall] must automatically
21-33 be restored to good standing on the first day following the period of
21-34 suspension. The Executive Secretary[,] of the Board, when
21-35 notifying the respondent of the penalty imposed by the Board, shall
21-36 inform the respondent of the date on which the certificate, license or
21-37 permit will be so restored.
21-38 Secs. 38 and 39. (Deleted by amendment.)
21-39 Sec. 40. NRS 453.1545 is hereby amended to read as follows:
21-40 453.1545 1. The Board and the Division shall cooperatively
21-41 develop a computerized program to track each prescription for a
21-42 controlled substance listed in schedule II, III or IV that is filled by a
21-43 pharmacy that is registered with the Board[.] or that is dispensed by
21-44 a practitioner who is registered with the Board. The program must:
21-45 (a) Be designed to provide information regarding:
22-1 (1) The inappropriate use by a patient of controlled
22-2 substances listed in schedules II, III and IV to pharmacies,
22-3 practitioners and appropriate state agencies to prevent the improper
22-4 or illegal use of those controlled substances; and
22-5 (2) Statistical data relating to the use of those controlled
22-6 substances that is not specific to a particular patient.
22-7 (b) Be administered by the Board, the Division, the Health
22-8 Division of the Department of Human Resources and various
22-9 practitioners, representatives of professional associations for
22-10 practitioners, representatives of occupational licensing boards and
22-11 prosecuting attorneys selected by the Board and the Division.
22-12 (c) Not infringe on the legal use of a controlled substance for the
22-13 management of severe or intractable pain.
22-14 2. The Board and the Division must have access to the program
22-15 established pursuant to subsection 1 to identify any suspected
22-16 fraudulent or illegal activity related to the dispensing of controlled
22-17 substances.
22-18 3. The Board or the Division shall report any activity it
22-19 reasonably suspects may be fraudulent or illegal to the appropriate
22-20 law enforcement agency or occupational licensing board and
22-21 provide the law enforcement agency or occupational licensing board
22-22 with the relevant information obtained from the program for further
22-23 investigation.
22-24 4. Information obtained from the program relating to a
22-25 practitioner or a patient is confidential and, except as otherwise
22-26 provided by this section, must not be disclosed to any person. That
22-27 information must be disclosed:
22-28 (a) Upon the request of a person about whom the information
22-29 requested concerns or upon the request on his behalf by his attorney;
22-30 or
22-31 (b) Upon the lawful order of a court of competent jurisdiction.
22-32 5. The Board and the Division may apply for any available
22-33 grants and accept any gifts, grants or donations to assist in
22-34 developing and maintaining the program required by this section.
22-35 Sec. 40.5. NRS 453.375 is hereby amended to read as follows:
22-36 453.375 A controlled substance may be possessed and
22-37 administered by the following persons:
22-38 1. A practitioner.
22-39 2. A registered nurse licensed to practice professional nursing
22-40 or licensed practical nurse, at the direction of a physician, physician
22-41 assistant, dentist, podiatric physician or advanced practitioner of
22-42 nursing, or pursuant to a chart order, for administration to a patient
22-43 at another location.
22-44 3. An advanced emergency medical technician:
22-45 (a) As authorized by regulation of:
23-1 (1) The State Board of Health in a county whose population
23-2 is less than 100,000; or
23-3 (2) A county or district board of health in a county whose
23-4 population is 100,000 or more; and
23-5 (b) In accordance with any applicable regulations of:
23-6 (1) The State Board of Health in a county whose population
23-7 is less than 100,000;
23-8 (2) A county board of health in a county whose population is
23-9 100,000 or more; or
23-10 (3) A district board of health created pursuant to NRS
23-11 439.370 in any county.
23-12 4. A respiratory therapist,at the direction of a physician or
23-13 physician assistant.
23-14 5. A medical student, student in training to become a physician
23-15 assistant or student nurse in the course of his studies at an approved
23-16 college of medicine or school of professional or practical nursing, at
23-17 the direction of a physician or physician assistant and:
23-18 (a) In the presence of a physician, physician assistant or a
23-19 registered nurse; or
23-20 (b) Under the supervision of a physician, physician assistant or a
23-21 registered nurse if the student is authorized by the college or school
23-22 to administer the substance outside the presence of a physician,
23-23 physician assistant or nurse.
23-24 A medical student or student nurse may administer a controlled
23-25 substance in the presence or under the supervision of a registered
23-26 nurse alone only if the circumstances are such that the registered
23-27 nurse would be authorized to administer it personally.
23-28 6. An ultimate user or any person whom the ultimate user
23-29 designates pursuant to a written agreement.
23-30 7. Any person designated by the head of a correctional
23-31 institution.
23-32 8. A veterinary technician at the direction of his supervising
23-33 veterinarian.
23-34 9. In accordance with applicable regulations of the State Board
23-35 of Health, an employee of a residential facility for groups, as
23-36 defined in NRS 449.017, pursuant to a written agreement entered
23-37 into by the ultimate user.
23-38 10. In accordance with applicable regulations of the State
23-39 Board of Pharmacy, an animal control officer, a wildlife biologist or
23-40 an employee designated by a federal, state or local governmental
23-41 agency whose duties include the control of domestic, wild and
23-42 predatory animals.
23-43 11. A person who is enrolled in a training program to become
23-44 an advanced emergency medical technician, respiratory therapist
23-45 or veterinary technician if the person possesses and administers
24-1 the controlled substance in the same manner and under the same
24-2 conditions that apply, respectively, to an advanced emergency
24-3 medical technician, respiratory therapist or veterinary technician
24-4 who may possess and administer the controlled substance, and
24-5 under the direct supervision of a person licensed or registered to
24-6 perform the respective medical art or a supervisor of such a
24-7 person.
24-8 Sec. 41. NRS 453.431 is hereby amended to read as follows:
24-9 453.431 1. A pharmacist shall not knowingly fill or refill any
24-10 prescription for a controlled substance for use by a person other than
24-11 the person for whom the prescription was originally issued.
24-12 2. A person shall not furnish a false name or address while
24-13 attempting to obtain a controlled substance or a prescription for a
24-14 controlled substance. A person prescribing, administering or
24-15 dispensing a controlled substance may request proper identification
24-16 from a person requesting controlled substances.
24-17 3. A pharmacist shall not fill a prescription for a controlled
24-18 substance if the prescription shows evidence of alteration, erasure or
24-19 addition, unless he obtains approval of the practitioner who issued
24-20 the prescription.
24-21 4. A pharmacist shall not fill a prescription for a controlled
24-22 substance classified in schedule II unless it is tendered on or before
24-23 the 14th day after the date of issue. This subsection does not
24-24 prohibit a practitioner from issuing a prescription on which he
24-25 indicates that the prescription may not be filled until the date
24-26 indicated on the prescription, which must not be later than 6
24-27 months after the date the prescription is issued.
24-28 5. A person who violates this section is guilty of a category C
24-29 felony and shall be punished as provided in NRS 193.130.
24-30 Sec. 41.5. NRS 454.213 is hereby amended to read as follows:
24-31 454.213 A drug or medicine referred to in NRS 454.181 to
24-32 454.371, inclusive, may be possessed and administered by:
24-33 1. A practitioner.
24-34 2. A physician assistant at the direction of his supervising
24-35 physician or a licensed dental hygienist acting in the office of and
24-36 under the supervision of a dentist.
24-37 3. Except as otherwise provided in subsection 4, a registered
24-38 nurse licensed to practice professional nursing or licensed practical
24-39 nurse, at the direction of a prescribing physician, physician assistant,
24-40 dentist, podiatric physician or advanced practitioner of nursing, or
24-41 pursuant to a chart order, for administration to a patient at another
24-42 location.
24-43 4. In accordance with applicable regulations of the Board, a
24-44 registered nurse licensed to practice professional nursing or licensed
24-45 practical nurse who is:
25-1 (a) Employed by a health care agency or health care facility that
25-2 is authorized to provide emergency care, or to respond to the
25-3 immediate needs of a patient, in the residence of the patient; and
25-4 (b) Acting under the direction of the medical director of that
25-5 agency or facility who works in this state.
25-6 5. An intermediate emergency medical technician or an
25-7 advanced emergency medical technician, as authorized by
25-8 regulation of the State Board of Pharmacy and in accordance with
25-9 any applicable regulations of:
25-10 (a) The State Board of Health in a county whose population is
25-11 less than 100,000;
25-12 (b) A county board of health in a county whose population is
25-13 100,000 or more; or
25-14 (c) A district board of health created pursuant to NRS 439.370
25-15 in any county.
25-16 6. A respiratory therapist employed in a health care facility.
25-17 The therapist may possess and administer respiratory products only
25-18 at the direction of a physician.
25-19 7. A dialysis technician, under the direction or supervision of a
25-20 physician or registered nurse only if the drug or medicine is used for
25-21 the process of renal dialysis.
25-22 8. A medical student or student nurse in the course of his
25-23 studies at an approved college of medicine or school of professional
25-24 or practical nursing, at the direction of a physician and:
25-25 (a) In the presence of a physician or a registered nurse; or
25-26 (b) Under the supervision of a physician or a registered nurse if
25-27 the student is authorized by the college or school to administer the
25-28 drug or medicine outside the presence of a physician or
25-29 nurse.
25-30 A medical student or student nurse may administer a dangerous drug
25-31 in the presence or under the supervision of a registered nurse alone
25-32 only if the circumstances are such that the registered nurse would be
25-33 authorized to administer it personally.
25-34 9. Any person designated by the head of a correctional
25-35 institution.
25-36 10. An ultimate user or any person designated by the ultimate
25-37 user pursuant to a written agreement.
25-38 11. A nuclear medicine technologist, at the direction of a
25-39 physician and in accordance with any conditions established by
25-40 regulation of the Board.
25-41 12. A radiologic technologist, at the direction of a physician
25-42 and in accordance with any conditions established by regulation of
25-43 the Board.
26-1 13. A chiropractic physician, but only if the drug or medicine
26-2 is a topical drug used for cooling and stretching external tissue
26-3 during therapeutic treatments.
26-4 14. A physical therapist, but only if the drug or medicine is a
26-5 topical drug which is:
26-6 (a) Used for cooling and stretching external tissue during
26-7 therapeutic treatments; and
26-8 (b) Prescribed by a licensed physician for:
26-9 (1) Iontophoresis; or
26-10 (2) The transmission of drugs through the skin using
26-11 ultrasound.
26-12 15. In accordance with applicable regulations of the State
26-13 Board of Health, an employee of a residential facility for groups, as
26-14 defined in NRS 449.017, pursuant to a written agreement entered
26-15 into by the ultimate user.
26-16 16. A veterinary technician at the direction of his supervising
26-17 veterinarian.
26-18 17. In accordance with applicable regulations of the Board, a
26-19 registered pharmacist who:
26-20 (a) Is trained in and certified to carry out standards and practices
26-21 for immunization programs;
26-22 (b) Is authorized to administer immunizations pursuant to
26-23 written protocols from a physician; and
26-24 (c) Administers immunizations in compliance with the
26-25 “Standards of Immunization Practices” recommended and approved
26-26 by the United States Public Health Service Advisory Committee on
26-27 Immunization Practices.
26-28 18. A person who is enrolled in a training program to become
26-29 a physician assistant, dental hygienist, intermediate emergency
26-30 medical technician, advanced emergency medical technician,
26-31 respiratory therapist, dialysis technician, nuclear medicine
26-32 technologist, radiologic technologist, physical therapist or
26-33 veterinary technician if the person possesses and administers the
26-34 drug or medicine in the same manner and under the same
26-35 conditions that apply, respectively, to a physician assistant, dental
26-36 hygienist, intermediate emergency medical technician, advanced
26-37 emergency medical technician, respiratory therapist, dialysis
26-38 technician, nuclear medicine technologist, radiologic technologist,
26-39 physical therapist or veterinary technician who may possess and
26-40 administer the drug or medicine, and under the direct supervision
26-41 of a person licensed or registered to perform the respective
26-42 medical art or a supervisor of such a person.
27-1 Sec. 42. NRS 689A.04045 is hereby amended to read as
27-2 follows:
27-3 689A.04045 1. Except as otherwise provided in this section,
27-4 a policy of health insurance which provides coverage for
27-5 prescription drugs must not limit or exclude coverage for a drug if
27-6 the drug:
27-7 (a) Had previously been approved for coverage by the insurer
27-8 for a medical condition of an insured and the insured’s provider of
27-9 health care determines, after conducting a reasonable investigation,
27-10 that none of the drugs which are otherwise currently approved for
27-11 coverage are medically appropriate for the insured; and
27-12 (b) Is appropriately prescribed and considered safe and effective
27-13 for treating the medical condition of the insured.
27-14 2. The provisions of subsection 1 do not:
27-15 (a) Apply to coverage for any drug that is prescribed for a use
27-16 that is different from the use for which that drug has been approved
27-17 for marketing by the Food and Drug Administration;
27-18 (b) Prohibit:
27-19 (1) The insurer from charging a deductible, copayment or
27-20 coinsurance for the provision of benefits for prescription drugs to
27-21 the insured or from establishing, by contract, limitations on the
27-22 maximum coverage for prescription drugs;
27-23 (2) A provider of health care from prescribing another drug
27-24 covered by the policy that is medically appropriate for the insured;
27-25 or
27-26 (3) The substitution of another drug pursuant to NRS
27-27 639.23286 or 639.2583 to [639.2599,] 639.2597, inclusive; or
27-28 (c) Require any coverage for a drug after the term of the policy.
27-29 3. Any provision of a policy subject to the provisions of this
27-30 chapter that is delivered, issued for delivery or renewed on or after
27-31 October 1, 2001, which is in conflict with this section is void.
27-32 Sec. 43. NRS 689B.0368 is hereby amended to read as
27-33 follows:
27-34 689B.0368 1. Except as otherwise provided in this section, a
27-35 policy of group health insurance which provides coverage for
27-36 prescription drugs must not limit or exclude coverage for a drug if
27-37 the drug:
27-38 (a) Had previously been approved for coverage by the insurer
27-39 for a medical condition of an insured and the insured’s provider of
27-40 health care determines, after conducting a reasonable investigation,
27-41 that none of the drugs which are otherwise currently approved for
27-42 coverage are medically appropriate for the insured; and
27-43 (b) Is appropriately prescribed and considered safe and effective
27-44 for treating the medical condition of the insured.
27-45 2. The provisions of subsection 1 do not:
28-1 (a) Apply to coverage for any drug that is prescribed for a use
28-2 that is different from the use for which that drug has been approved
28-3 for marketing by the Food and Drug Administration;
28-4 (b) Prohibit:
28-5 (1) The insurer from charging a deductible, copayment or
28-6 coinsurance for the provision of benefits for prescription drugs to
28-7 the insured or from establishing, by contract, limitations on the
28-8 maximum coverage for prescription drugs;
28-9 (2) A provider of health care from prescribing another drug
28-10 covered by the policy that is medically appropriate for the insured;
28-11 or
28-12 (3) The substitution of another drug pursuant to NRS
28-13 639.23286 or 639.2583 to [639.2599,] 639.2597, inclusive; or
28-14 (c) Require any coverage for a drug after the term of the policy.
28-15 3. Any provision of a policy subject to the provisions of this
28-16 chapter that is delivered, issued for delivery or renewed on or after
28-17 October 1, 2001, which is in conflict with this section is void.
28-18 Sec. 44. NRS 689C.168 is hereby amended to read as follows:
28-19 689C.168 1. Except as otherwise provided in this section, a
28-20 health benefit plan which provides coverage for prescription drugs
28-21 must not limit or exclude coverage for a drug if the drug:
28-22 (a) Had previously been approved for coverage by the carrier for
28-23 a medical condition of an insured and the insured’s provider of
28-24 health care determines, after conducting a reasonable investigation,
28-25 that none of the drugs which are otherwise currently approved for
28-26 coverage are medically appropriate for the insured; and
28-27 (b) Is appropriately prescribed and considered safe and effective
28-28 for treating the medical condition of the insured.
28-29 2. The provisions of subsection 1 do not:
28-30 (a) Apply to coverage for any drug that is prescribed for a use
28-31 that is different from the use for which that drug has been approved
28-32 for marketing by the Food and Drug Administration;
28-33 (b) Prohibit:
28-34 (1) The carrier from charging a deductible, copayment or
28-35 coinsurance for the provision of benefits for prescription drugs to
28-36 the insured or from establishing, by contract, limitations on the
28-37 maximum coverage for prescription drugs;
28-38 (2) A provider of health care from prescribing another drug
28-39 covered by the plan that is medically appropriate for the insured; or
28-40 (3) The substitution of another drug pursuant to NRS
28-41 639.23286 or 639.2583 to [639.2599,] 639.2597, inclusive; or
28-42 (c) Require any coverage for a drug after the term of the plan.
28-43 3. Any provision of a health benefit plan subject to the
28-44 provisions of this chapter that is delivered, issued for delivery or
29-1 renewed on or after October 1, 2001, which is in conflict with this
29-2 section is void.
29-3 Sec. 45. NRS 695A.184 is hereby amended to read as follows:
29-4 695A.184 1. Except as otherwise provided in this section, a
29-5 benefit contract which provides coverage for prescription drugs
29-6 must not limit or exclude coverage for a drug if the drug:
29-7 (a) Had previously been approved for coverage by the society
29-8 for a medical condition of an insured and the insured’s provider of
29-9 health care determines, after conducting a reasonable investigation,
29-10 that none of the drugs which are otherwise currently approved for
29-11 coverage are medically appropriate for the insured; and
29-12 (b) Is appropriately prescribed and considered safe and effective
29-13 for treating the medical condition of the insured.
29-14 2. The provisions of subsection 1 do not:
29-15 (a) Apply to coverage for any drug that is prescribed for a use
29-16 that is different from the use for which that drug has been approved
29-17 for marketing by the Food and Drug Administration;
29-18 (b) Prohibit:
29-19 (1) The society from charging a deductible, copayment or
29-20 coinsurance for the provision of benefits for prescription drugs to
29-21 the insured or from establishing, by contract, limitations on the
29-22 maximum coverage for prescription drugs;
29-23 (2) A provider of health care from prescribing another drug
29-24 covered by the benefit contract that is medically appropriate for the
29-25 insured; or
29-26 (3) The substitution of another drug pursuant to NRS
29-27 639.23286 or 639.2583 to [639.2599,] 639.2597, inclusive; or
29-28 (c) Require any coverage for a drug after the term of the benefit
29-29 contract.
29-30 3. Any provision of a benefit contract subject to the provisions
29-31 of this chapter that is delivered, issued for delivery or renewed on or
29-32 after October 1, 2001, which is in conflict with this section is void.
29-33 Sec. 46. NRS 695B.1905 is hereby amended to read as
29-34 follows:
29-35 695B.1905 1. Except as otherwise provided in this section, a
29-36 contract for hospital or medical services which provides coverage
29-37 for prescription drugs must not limit or exclude coverage for a drug
29-38 if the drug:
29-39 (a) Had previously been approved for coverage by the insurer
29-40 for a medical condition of an insured and the insured’s provider of
29-41 health care determines, after conducting a reasonable investigation,
29-42 that none of the drugs which are otherwise currently approved for
29-43 coverage are medically appropriate for the insured; and
29-44 (b) Is appropriately prescribed and considered safe and effective
29-45 for treating the medical condition of the insured.
30-1 2. The provisions of subsection 1 do not:
30-2 (a) Apply to coverage for any drug that is prescribed for a use
30-3 that is different from the use for which that drug has been approved
30-4 for marketing by the Food and Drug Administration;
30-5 (b) Prohibit:
30-6 (1) The insurer from charging a deductible, copayment or
30-7 coinsurance for the provision of benefits for prescription drugs to
30-8 the insured or from establishing, by contract, limitations on the
30-9 maximum coverage for prescription drugs;
30-10 (2) A provider of health care from prescribing another drug
30-11 covered by the contract that is medically appropriate for the insured;
30-12 or
30-13 (3) The substitution of another drug pursuant to NRS
30-14 639.23286 or 639.2583 to [639.2599,] 639.2597, inclusive; or
30-15 (c) Require any coverage for a drug after the term of the
30-16 contract.
30-17 3. Any provision of a contract for hospital or medical services
30-18 subject to the provisions of this chapter that is delivered, issued for
30-19 delivery or renewed on or after October 1, 2001, which is in conflict
30-20 with this section is void.
30-21 Sec. 47. NRS 695C.1734 is hereby amended to read as
30-22 follows:
30-23 695C.1734 1. Except as otherwise provided in this section,
30-24 evidence of coverage which provides coverage for prescription
30-25 drugs must not limit or exclude coverage for a drug if the drug:
30-26 (a) Had previously been approved for coverage by the health
30-27 maintenance organization or insurer for a medical condition of an
30-28 enrollee and the enrollee’s provider of health care determines, after
30-29 conducting a reasonable investigation, that none of the drugs which
30-30 are otherwise currently approved for coverage are medically
30-31 appropriate for the enrollee; and
30-32 (b) Is appropriately prescribed and considered safe and effective
30-33 for treating the medical condition of the enrollee.
30-34 2. The provisions of subsection 1 do not:
30-35 (a) Apply to coverage for any drug that is prescribed for a use
30-36 that is different from the use for which that drug has been approved
30-37 for marketing by the Food and Drug Administration;
30-38 (b) Prohibit:
30-39 (1) The health maintenance organization or insurer from
30-40 charging a deductible, copayment or coinsurance for the provision
30-41 of benefits for prescription drugs to the enrollee or from
30-42 establishing, by contract, limitations on the maximum coverage for
30-43 prescription drugs;
31-1 (2) A provider of health care from prescribing another drug
31-2 covered by the evidence of coverage that is medically appropriate
31-3 for the enrollee; or
31-4 (3) The substitution of another drug pursuant to NRS
31-5 639.23286 or 639.2583 to [639.2599,] 639.2597, inclusive; or
31-6 (c) Require any coverage for a drug after the term of the
31-7 evidence of coverage.
31-8 3. Any provision of an evidence of coverage subject to the
31-9 provisions of this chapter that is delivered, issued for delivery or
31-10 renewed on or after October 1, 2001, which is in conflict with this
31-11 section is void.
31-12 Sec. 48. NRS 695F.156 is hereby amended to read as follows:
31-13 695F.156 1. Except as otherwise provided in this section,
31-14 evidence of coverage which provides coverage for prescription
31-15 drugs must not limit or exclude coverage for a drug if the drug:
31-16 (a) Had previously been approved for coverage by the prepaid
31-17 limited health service organization for a medical condition of an
31-18 enrollee and the enrollee’s provider of health care determines, after
31-19 conducting a reasonable investigation, that none of the drugs which
31-20 are otherwise currently approved for coverage are medically
31-21 appropriate for the enrollee; and
31-22 (b) Is appropriately prescribed and considered safe and effective
31-23 for treating the medical condition of the enrollee.
31-24 2. The provisions of subsection 1 do not:
31-25 (a) Apply to coverage for any drug that is prescribed for a use
31-26 that is different from the use for which that drug has been approved
31-27 for marketing by the Food and Drug Administration;
31-28 (b) Prohibit:
31-29 (1) The organization from charging a deductible, copayment
31-30 or coinsurance for the provision of benefits for prescription drugs to
31-31 the enrollee or from establishing, by contract, limitations on the
31-32 maximum coverage for prescription drugs;
31-33 (2) A provider of health care from prescribing another drug
31-34 covered by the evidence of coverage that is medically appropriate
31-35 for the enrollee; or
31-36 (3) The substitution of another drug pursuant to NRS
31-37 639.23286 or 639.2583 to [639.2599,] 639.2597, inclusive; or
31-38 (c) Require any coverage for a drug after the term of the
31-39 evidence of coverage.
31-40 3. Any provision of an evidence of coverage subject to the
31-41 provisions of this chapter that is delivered, issued for delivery or
31-42 renewed on or after October 1, 2001, which is in conflict with this
31-43 section is void.
32-1 Sec. 49. NRS 695G.166 is hereby amended to read as follows:
32-2 695G.166 1. Except as otherwise provided in this section, a
32-3 health care plan which provides coverage for prescription drugs
32-4 must not limit or exclude coverage for a drug if the drug:
32-5 (a) Had previously been approved for coverage by the managed
32-6 care organization for a medical condition of an insured and the
32-7 insured’s provider of health care determines, after conducting a
32-8 reasonable investigation, that none of the drugs which are otherwise
32-9 currently approved for coverage are medically appropriate for the
32-10 insured; and
32-11 (b) Is appropriately prescribed and considered safe and effective
32-12 for treating the medical condition of the insured.
32-13 2. The provisions of subsection 1 do not:
32-14 (a) Apply to coverage for any drug that is prescribed for a use
32-15 that is different from the use for which that drug has been approved
32-16 for marketing by the Food and Drug Administration;
32-17 (b) Prohibit:
32-18 (1) The organization from charging a deductible, copayment
32-19 or coinsurance for the provision of benefits for prescription drugs to
32-20 the insured or from establishing, by contract, limitations on the
32-21 maximum coverage for prescription drugs;
32-22 (2) A provider of health care from prescribing another drug
32-23 covered by the plan that is medically appropriate for the insured; or
32-24 (3) The substitution of another drug pursuant to NRS
32-25 639.23286 or 639.2583 to [639.2599,] 639.2597, inclusive; or
32-26 (c) Require any coverage for a drug after the term of the plan.
32-27 3. Any provision of a health care plan subject to the provisions
32-28 of this chapter that is delivered, issued for delivery or renewed on or
32-29 after October 1, 2001, which is in conflict with this section is void.
32-30 Sec. 50. NRS 639.0152, 639.133, 639.205, 639.2323 and
32-31 639.2599 are hereby repealed.
32-32 LEADLINES OF REPEALED SECTIONS
32-33 639.0152 “Supportive personnel” defined.
32-34 639.133 Registration of pharmacist not possessing formal
32-35 educational requirements.
32-36 639.205 Inactive status.
32-37 639.2323 Nuclear pharmacy: Publications required on
32-38 premises.
32-39 639.2599 Display of notice regarding substitution.
32-40 H